{"entity":{"id":"nct07765446","kind":"trial","name":"Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel","aka":[],"tldr":"A phase 2 trial of SIR2501 in advanced solid tumours, run by Sironax USA, Inc., now recruiting.","summary":"Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel is a phase 2 interventional study registered as NCT07765446 by Sironax USA, Inc., with 18 participants planned, started 2026-08-21 and due to reach its primary completion in 2027-12-31. Interventions recorded: SIR2501.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07765446","url":"https://clinicaltrials.gov/study/NCT07765446"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07765446","phase":"2","setting":"A Phase 2, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SIR2501 and Its Potential to Address Paclitaxel-Induced Peripheral Neuropathy","sponsor":"Sironax USA, Inc.","enrolled":18,"outcomes":[]},"route":"/trials/nct07765446/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}